Пахихороидальные состояния

    1. Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept source optical coherence tomography. Retina. 2016;36:499-516.

    2. Warrow DJ, Hoang QV, Freund KB. Pachychoroid pigment epitheliopathy. Retina. 2013;33:1659-1672.

    3. Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M. Indocyanine green angiography of pachychoroid pigment epitheliopathy. Retina. 2018;38(9):1668-1674.

    4. Balaratnasingam C, Lee WK, Koizumi H, et al. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina. 2016;36:1-8.

    5. Cheung C, Lee W, Koizumi H, et al. Pachychoroid disease. Eye. 2019;33(1):14-33.

    6. Pang CE, Freund KB. Pachychoroid pigment epitheliopathy may masquerade as acute retinal pigment epitheliitis. Invest Ophthalmol Vis Sci. 2014;55:5252.

    7. Yang L, Jonas JB, Wei W. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol. 2013;91:e358-62.

    8. Akkaya S. Spectrum of pachychoroid disease. Int Ophthalmol. 2018;38:2239-2246.

    9. Karacorlu M, Ersoz MG, Arf S, et al. Long-term follow-up of pachychoroid pigment epitheliopathy and lesion characteristics. Graefes Arch Clin Exp Ophthalmol. 2018256:2319-2326.

    10. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121:26-34.

    11. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormalchoroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003;87:709-12.

    12. Lee WK, Baek J, Dansingani KK, Lee JH, Freund KB. Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness. Retina. 2016;36(suppl 1):S73–S82.

    13.Lee M, Lee H, Kim HC, et al. Changes in stromal and luminal areas of the choroid in pachychoroid diseases: Insights into the pathophsiology of pachychoroid diseases. Invest Ophthalmol Vis Sci. 2018;59:4896-4908.

    14. Saito M, Saito W, Hashimoto Y, et al. Macular choroidal blood flow velocity decreases with regression of acute central serous chorioretinopathy. Br J Ophthalmol. 2013;97:775- 780.

    15. Saito M, Saito W, Hirooka K, et al. Pulse waveform changes in macular choroidal hemodynamics with regression of acute central serous chorioretinopathy. Invest Ophthalmol Vis Sci. 2015;56:6515-6522.

    16. Melrose MA, Magargal LE, Goldberg RE, Annesley WH Jr. Subretinal neovascular membranes associated with choroidal nonperfusion and retinal ischemia. Ann Ophthalmol. 1987; 19(10):396-399.

    17. Baek J, Kook L, Lee WK. Choriocapillaris flow impairments in association with pachyvessel in early stages of pachychoroid. Sci Rep. 2019;9:5565.

    18. Ersoz MG, Karacorlu M, Arf S et al (2018) Pachychoroid pigment epitheliopathy in fellow eyes of patients with unilateral central serous chorioretinopathy. Br J Ophthalmol. 102:473-478.

    19. Ersoz MG, Karacorlu M, Arf S, et al (2018) Outer nuclear layer thinning in pachychoroid pigment epitheliopathy. Retina. 38:957-961.

    20. Gallego-Pinazo R, Dolz-Marco R, Gomez-Ulla F et al (2014) Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 3:111-115.

    21. Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35:1-9.

    22. Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with central serous chorioretinopathy: assessment of haller and sattler layers. Retina. 2016;36:1652–7.

    23. Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115:2229–34.

    24. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117:1792–9.

    25. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288–98.

    26. Izumi T, Koizumi H, Maruko I, et al. Structural analyses ofchoroid after half-dose verteporfin photodynamic therapy forcentral serous chorioretinopathy. Br J Ophthalmol. 2017;101:433–7.

    27. Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85-93.

    28. Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121:1073–8.

    29. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65.

    30. Lai TY, Wong RL, Chan WM. Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2015;113:T8.

    31. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35:2505–15.

    32. Ghadiali Q, Jung JJ, Yu S, Patel SN, Yannuzzi LA. Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study. Retina. 2016;36:611–8.

    33.Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012;32:1829–37.

    34. Dansingani KK, Gal-Or O, Sadda SR, et al. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of ‘expanded spectra'da review. Clin Exp Ophthalmol. 2018;46:189-200.

    35. Sato T, Kishi S, Watanabe G, Matsumoto H, Mukai R. Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy. Retina. 2007;27:589–94.

    36. Dansingani KK, Balaratnasingam C, Klufas MA, Sarraf D, Freund KB. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am J Ophthalmol. 2015;160:1243–54.

    37. Chhablani J, Kozak I, Pichi F, et al. Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina. 2015;35:2489–97.

    38. Lai TYY, Staurenghi G, Lanzetta P, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38(8):1464-1477.

    39. Cheng CY, Yamashiro K, Chen LJ, et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun. 2015;6:6063.

    40. Hata M, Yamashiro K, Ooto S, et al. Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:292–8.

    41. Lee JH, Lee WK. One-year results of adjunctive photodynamic therapy for type 1 neovascularization associated with thickened choroid. Retina. 2016;36:889–95.

    42. Kleiner RC, Brucker AJ, Johnston RL. The posterior uveal bleeding syndrome. Retina. 1990;10(1):9-17.

    43. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1-8.

    44. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100–10.

    45.Cheung CMG, Lai TYY, Ruamviboonsuk P. Polypoidal Choroidal vasculopathy: Definition, Pathogenesis, Diagnosis, and Management. Ophthalmology. 2018;125:708-724.

    46. Terasaki H, Miyake Y, Suzuki T, et al. Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation. Br J Ophthalmol. 2002;86(3):321-327.

    47. Matsuoka M, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol. 2004;88(6):809-815.

    48. Lee MY, Lee WK, Baek J, et al. Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growthfactor. Am J Ophthalmol. 2013;156(2):343-348.

    49. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epitheliumderived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006;141(3):456-462.

    50. Sasaki S, Miyazaki D, Miyake K, et al. Associations of IL-23 with polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2012; 53(7):3424-3430.

    51. Zhao M, Bai Y, Xie W, et al. Interleukin-1beta level is increased in vitreous of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). PLoS One. 2015;10(5):e0125150.

    52. Nakashizuka H, Yuzawa M. Hyalinization of choroidal vessels in polypoidal choroidal vasculopathy. Surv Ophthalmol. 2011;56:278–9.

    53. Chan WM, Lam DS, Lai TY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology. 2004;111:1576–84.

    54. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology. 2008;115:141–6.

    55. Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol. 2005;243:973–9.

    56. Koh A, Lai TYY, Takahashi K, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206–13.

    57. Wong TY, Ogura Y, Lee WK, et al, PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019;204:80-89.

    58. Lee WK, Iida T, Ogura Y, et al, PLANET Investigators. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018 1;136(7):786-793.

    59. Chung H, Byeon SH, Freund KB. Focal choroidal excavation and its association with pachychoroid spectrum disorders: A Review of the Literature and Multimodal Imaging Findings. Retina. 2017;37(2):199-221.

    60. Phasukkijwatana N, Freund KB, Dolz-Marco R, et al. Peripapillary pachychoroid syndrome. Retina. 2018;38(9):1652-1667.